TY - JOUR T1 - The Mutational Landscape of the SCAN-B Real-World Primary Breast Cancer Transcriptome JF - bioRxiv DO - 10.1101/2020.01.30.926733 SP - 2020.01.30.926733 AU - Christian Brueffer AU - Sergii Gladchuk AU - Christof Winter AU - Johan Vallon-Christersson AU - Cecilia Hegardt AU - Jari Häkkinen AU - Anthony M. George AU - Yilun Chen AU - Anna Ehinger AU - Christer Larsson AU - Niklas Loman AU - Martin Malmberg AU - Lisa Rydén AU - Åke Borg AU - Lao H. Saal Y1 - 2020/01/01 UR - http://biorxiv.org/content/early/2020/01/31/2020.01.30.926733.abstract N2 - Breast cancer is a disease of genomic alterations, of which the complete panorama of somatic mutations and how these relate to molecular subtypes and therapy response is incompletely understood. Within the Sweden Cancerome Analysis Network–Breast project (SCAN-B; ClinicalTrials.gov NCT02306096), an ongoing study elucidating the tumor transcriptomic profiles for thousands of breast cancers prospectively, we developed an optimized pipeline for detection of single nucleotide variants and small insertions and deletions from RNA sequencing (RNA-seq) data, and profiled a large real-world population-based cohort of 3,217 breast tumors. We use it to describe the mutational landscape of primary breast cancer viewed through the transcriptome of a large population-based cohort of patients, and relate it to patient overall survival. We demonstrate that RNA-seq can be used to call mutations in important breast cancer genes such as PIK3CA, TP53, and ERBB2, as well as the status of key molecular pathways and tumor mutational burden, and identify potentially druggable genes in 86.8% percent of tumors. To make this rich and growing mutational portraiture of breast cancer available for the wider research community, we developed an open source web-based application, the SCAN-B MutationExplorer, accessible at http://oncogenomics.bmc.lu.se/MutationExplorer. These results add another dimension to the use of RNA-seq as a potential clinical tool, where both gene expression-based and gene mutation-based biomarkers can be interrogated simultaneously and in real-time within one week of tumor sampling. ER -